Open Accessibility Menu

3D Ultrasound/MRI Fusion Biopsy for Diagnosing Prostate Cancer

Highly Targeted Prostate Cancer Diagnostics

Continually on the forefront of groundbreaking technology, weoffer patients even more targeted prostate cancer diagnostics leading to more precise treatment planning and better clinical outcomes.
The 3D Ultrasound/ MRI Fusion Biopsy for Prostate Cancer “fuses” detailed MRI scans with live, real-time ultrasound images of the prostate. This provides urologists with the ability to pinpoint the exact prostate cancer location within the prostate gland and better identify the extent of disease. Several studies have demonstrated that this system provides a higher level of accuracy in diagnosis for patients at risk of prostate cancer.
The sophisticated technology includes:

  • The PROMAP-MR - combines 3D ultrasound and MRI to produce accurate 3D mapping of biopsy samples within multimodal images


  • The PROMAP-US - combines full 3D ultrasound and automatic organ tracking to create, visualize, and memorize a 3D map of “target” lesions and biopsy samples

promap us

How Does the 3D Ultrasound/MRI Fusion Biopsy for Prostate Cancer Work?

By combining advanced MRI imaging with 3D ultrasound technology, this biopsy system:

  • Creates a 3D map of the prostate
  • Identifies suspicious lesions or targets on MRI
  • Fuses or overlaps the 3D MRI image onto the 3D ultrasound image of the prostate
  • Accurately guides the biopsy needle into the target lesion
  • Stores a memory of the exact location of each biopsy sample

Am I a Candidate for the 3D Ultrasound/MRI Fusion Biopsy?

Several groups of patients can take advantage of this diagnostic tool including:

  • Men who have a current diagnosis of prostate cancer and have chosen Active Surveillance (watchful waiting), which typically requires periodic biopsies
  • Men who have a persistently rising PSA level despite having a previous 2D (2-dimensional) Transrectal Ultrasound (TRUS)-guided biopsy and prostate needle biopsy which was negative for cancer
  • Men who are found on traditional 2D TRUS-guided biopsy to have cells that are abnormal but cannot be confirmed as cancer
  • Men with a newly identified elevated PSA
  • Men previously treated for prostate cancer with radiation therapy or cryosurgery who have a rising PSA that suggests a possible recurrence of cancer in the prostate gland